Table 1. Demographics information and numbers of non-motor symptoms in NPRBD and PRBD groups.

	NPRBD group	PRBD group	P
Number (cases)	143	67
Male/Total [cases/total (%)]	77/143 (53.85%)	38/67 (56.72%)	0.697
Age [years, median (quartile)]	59.59 ± 10.63	60.91 ± 11.69	0.464
Age of disease onset (years, mean ± SD)	56.60 ± 11.36	55.93 ± 11.72	0.702
Disease duration [years, median (quartile)]	2.00 (1.00~4.00)	3.00 (1.35~6.00)	0.004 **
Hoehn-Yahr stage [stage, median (quartile)]	1.50 (1.50~2.50)	2.00 (1.50~2.50)	0.040 *
UPDRS III [points, mean ± SD]	22.18 ± 9.271	28.59 ± 15.218	0.005 **
Clinical phenotype [cases/total (%)]
Tremor type	44/143 (30.77%)	14/67 (20.90%)	0.136
Rigidity-bradykinesia type	17/143 (11.89%)	16/67 (23.88%)	0.026 *
Mixed type	82/143 (57.34%)	37/67 (55.22%)	0.773
Total numbers of NMS (cases, mean ± SD)	8.41 ± 5.27	11.17 ± 5.96	0.005 **
Numbers of pre-MS NMS [cases, median (quartile)]	1.00 (0~3.00)	2.00 (0.00~4.50)	0.083
Numbers of post-MS NMS [cases, median (quartile)]	5.00 (2.00~10.00)	7.00 (3.25~12.00)	0.067
Levodopa equivalent dose(mg, mean ±SD)	312.87 ± 101.67	331.12 ± 87.76	0.601

*: P<0.05,

**: P<0.01.